If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
187
results.
Updated on
19/04/2026 [06:51:00]
Results 25 to 50 of 187
Absstract of: CN121868254A
本发明涉及一种基于溶酶体的纳米载药颗粒及其应用，属于生物医药技术领域。本发明将溶酶体膜作为仿生膜来源包覆于药物纳米颗粒表面，在保持溶酶体膜结构稳定性的同时最大程度保留其天然存在的水解酶活性，使该纳米载药颗粒在体内递送过程中能够对肿瘤组织细胞外基质进行原位降解，从而有效削弱肿瘤组织的物理屏障，显著增强纳米药物在肿瘤组织中的渗透、分布及细胞摄取能力，并在此基础上改善免疫细胞进入肿瘤组织的条件，最终提高肿瘤治疗效果。
Absstract of: CN121872927A
本公开提供了一种脂质化合物和脂质纳米颗粒组合物，所述脂质化合物具有如式I所示结构。本公开提供的脂质纳米颗粒粒径分布较好，包封率高，且递送效果优异，能够满足体内递送的需求。
Absstract of: AU2024356988A1
Gas-filled nanobubbles for negatively charged genetic material delivery each includes a lipid membrane defining a gas containing internal void, wherein the lipid membrane includes a plurality of cationic lipids for complexing the negatively charged genetic material, an edge-activator incorporated between lipids of the membrane that enhances the flexibility of the membrane, and a membrane stiffener incorporated on an outer surface of the membrane that enhances the membrane's resistance to tearing.
Absstract of: WO2026077307A1
The present invention relates to the field of pharmaceutical technology, and in particular, to a neuroactive steroid solid dispersion, a solid dispersion composition, a method for preparing same and use thereof, and a medicament comprising the solid dispersion. The neuroactive steroid solid dispersion is obtained by melting and extruding a mixture of raw materials. In parts by mass, the mixture of raw materials comprises: 10 to 70 parts of a neuroactive steroid, 30 to 90 parts of a carrier material, and 0 to 60 parts of a plasticizer. The temperature of melting and extruding is < 160 °C. The neuroactive steroid in the neuroactive steroid solid dispersion is present in an amorphous state with a particle size of ≤ 200 nm, and features good oral bioavailability.
Absstract of: AU2024382503A1
A modified myoferlin protein capable of being packaged into extracellular vesicles (EVs) to facilitate release of EV payloads into recipient cells. The modified myoferlin protein enhances the release of payload at the targeted site. The present invention further provides a modified myoferlin-encapsulating nanoparticle comprising an exosome encapsulating any embodiment of the modified myoferlin of the present invention and one or more cargo RNAs to enhance release of the cargo RNAs at the targeted site.
Absstract of: WO2026077273A1
Provided are a composition containing a lipid nanoparticle (LNP) and an mRNA, and use thereof in the treatment of Gaucher disease. The composition contains an LNP and an mRNA, and the mRNA is encapsulated in the LNP or associated with the LNP, wherein the mRNA contains a nucleotide sequence encoding GBA1. The composition can effectively increase the expression and activity of β-glucocerebrosidase (β-GCase) in the serum and multiple target organs of a subject, and reduce the level of glucosylsphingosine (Lyso-GL1) therein. In addition, the composition possesses a relatively long half-life and has application prospects in the treatment of Gaucher disease.
Absstract of: AU2026202273A1
Abstract Compositions and articles comprising diamond particles, such as nanodiamond-based pharmaceutical compositions, are generally provided. In some embodiments, the articles and methods comprising (nano)diamond particles may be useful for monitoring and/or treating a disease (e.g., in a subject).
Absstract of: AU2025271161A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors. ov o v
Absstract of: AU2026202277A1
Abstract Disclosed therein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.
Absstract of: US20260102346A1
Provided is a drug delivery system, which in particular relates to a lipid composition. The shown lipid composition including a therapeutic agent and/or a prophylactic agent such as an RNA can be used for delivering the therapeutic agent and/or the prophylactic agent to a mammalian cell or organ, so as to, for example, regulate polypeptide, protein, or gene expression.
Absstract of: US20260102357A1
The present disclosure relates to a sulfur-containing ionizable lipid or a pharmaceutically acceptable salt thereof that incorporates a dithioacetal or dithioketal moiety in one or more of its lipophilic chains. Further provided is a delivery vehicle, such as a lipid nanoparticle, comprising the ionizable lipid for the delivery of cargo, such as nucleic acid.
Absstract of: AU2024336703A1
The present disclosure provides a pH-inducible structure-switching non-lamellar lipid nanovector (LNV) comprising: (a) at least one ionizable cationic lipid; (b) at least one phospholipid displaying a critical packing parameter (CPP) value > 1; and (c) at least one non-ionic surfactant displaying a CPP value < 1 at a molar concentration of between 20 % and 50 %, a method of making the LNV, a semi-synthetic extracellular vesicle (ssEV) resulting from the fusion of the LNV with extracellular vesicles at a pH higher than 6 and up to about 10, a kit and a use of the ssEV as a medicament or diagnostic agent.
Absstract of: WO2026080826A1
The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Absstract of: WO2026080622A1
Provided herein are compounds, such as compounds of Formula (I), and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of therapeutic cargo (e.g., polynucleotides, such as mRNA). In particular, the compounds described herein may be incorporated into lipid-based compositions to increase efficiency of delivery of a therapeutic agent(s) to a cell, a tissue, or a subject.
Absstract of: AU2024342596A1
The present invention relates to a material for local drug delivery, and use thereof. Specifically provided is a nanoparticle composition comprising a lipid component, the lipid component comprising a compound represented by formula (I). The nanoparticle composition of the present invention is delivered only at the site of administration.
Absstract of: WO2025052296A1
The present invention belongs to the field of biomedicine and drug delivery as well as pest and vector controls. The invention relates to a novel ionizable cationic lipid family incorporating silicon, which belongs to the trademark LipexSil® second generation lipids, wherein the tail is connected to the headgroup with biodegradable silyl acetal linker. Lipids containing silyl acetal linker(s) are state-of-the-art and are effective as ionizable cationic lipids in the formulation of empty or loaded lipid nanoparticles (LNPs). The novel linkers according to the invention are designed by means of proprietary borane catalysts WO2022129966. The invention describes the synthesis of the lipids of formula (I), formation and characterization of nanoparticles and biological experiments demonstrating that the lipid nanoparticles prepared with these novel lipids can efficiently deliver their cargo (e.g. RNA, DNA, mRNA, siRNA, dsRNA, pDNA, micro RNA, circular DNA, small biologically active molecules) into the cells.
Absstract of: US20260102348A1
An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided.In the formula, X represents —NR1— or —O—, R1 represents a hydrogen atom, a hydrocarbon group, or the like, R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R4, R5, R6, R7, R8, R9, R10, R11, and R12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R4 and R5, R10 and R5, R5 and R12, R4 and R6, R5 and R6, R6 and R7, R6 and R10, R12 and R7, and R7 and R8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a+b is equal to or greater than 1, and c+d is equal to or greater than 1.
Absstract of: WO2026080839A1
Immunoreactive peptides that can be used to detect or generate an immune response against Ehrlichia bacteria are provided. The immunoreactive peptides may be included in a diagnostic kit or pharmaceutical composition or vaccine composition. Methods of diagnosing or detecting exposure to E. canis in a mammalian subject, such as a dog, are also provided.
Absstract of: DE102024129442A1
Die Erfindung betrifft ein Konjugat umfassend mindestens ein Polymer und mindestens einen Antikörper oder mindestens ein Antikörperfragment, wobei das Polymer ausgewählt ist aus Poly(dimethyl acrylamid) (PDMA), Poly(oligoethylen glykol methacrylat) (POEGMA), Poly(2-hydroxypropyl methacrylamid) (PHPMA), Poly(vinylpyrrolidon) (PVP), Poly(2-methylsulfinyl)ethyl acrylat (PMSEA), Poly(6-O-methacyloyl-D-galactopyranose) (PMAGP), Acrylsäure (PAA), Poly(carboxybetain acrylat) (PCBA), Poly(vinylphosphonsäure) (PVPA), Poly(vinylbenzoesäure) (PVBzA), Poly(propylacrylsäure) (PPAA), Poly(styrolsulfonsäure) (PSS), Polyglycerol (PG) und Polyäpfelsäure (PMA) und das mindestens eine Antikörperfragment vorzugsweise mindestens einen Einzeldomänenantikörper (Nanobody) umfasst. Die Erfindung betrifft ferner die medizinische Verwendung des Konjugats, sein Herstellungsverfahren und Kits für dessen Anwendung.
Absstract of: WO2026078579A1
The present disclosure encompasses a lipid nanoparticle (LNP) comprising a polypeptide comprising a nucleic acid sequence encoding an engineered meganuclease that binds and cleaves a recognition sequence within a Hepatitis B virus (HBV) genome. Further, the disclosure encompasses pharmaceutical compositions comprising the LNPs, and the use of such compositions for inactivating a pol gene of an HBV genome or an HBV genome fragment in a cell and treating HBV infections or diseases associated with HBV infections.
Absstract of: WO2026077099A1
Provided are a protein/polyester/lipid-nucleic acid delivery system for delivering a nucleic acid drug, a preparation method therefor, and use thereof. The system is prepared from an aqueous phase comprising a nucleic acid and a protein, and an organic phase comprising a hydrophobic degradable aliphatic polyester and a derivative thereof, and an ionizable lipid and/or a cationic lipid material. The preparation method comprises mixing an aqueous phase and an organic phase by using a single emulsification technology or a high-pressure homogenization technology to obtain a protein nanoassembly for targeted nucleic acid delivery. The protein is albumin or a single-chain antibody-albumin fusion protein. The stable protein nanoassembly is applied to a targeted nucleic acid delivery platform, and is applied to a nucleic acid treatment drug for tumors, autoimmune diseases, or inflammatory diseases.
Absstract of: WO2026078444A1
The disclosure relates to the development of a nano-encapsulated extract of Mitragyna speciosa, commonly known as kratom, specifically designed for use in beverages, dietary supplements and natural health products. This extract is standardized to contain a precise concentration of mitragynine, the primary active alkaloid in kratom, ensuring consistent potency and efficacy in enhancing energy, alertness, and alleviating minor pain, such as delayed inset muscle soreness, associated with physical exertion. The disclosed technology outlines an extraction and encapsulation process that not only maximizes the yield of mitragynine but also ensures the removal of undesirable compounds and the encapsulation provides improved bioavailability, thereby enhancing the safety profile of the final product. The standardized extract may be easily incorporated into various beverage formulations, dietary supplements and natural health products, providing a reliable and effective herbal supplement option.
Absstract of: WO2026077978A1
The present invention relates to nanoparticles capable of crossing biological barriers. In particular, it refers to lipid nanoparticles configured to cross the blood-brain barrier, target skeletal tissues and effectively penetrate the skin barrier. The invention also encompasses compositions and applications thereof.
Absstract of: WO2026078426A1
A targeted nanocarrier for delivering drugs to targeted cells. The targeted nanocarrier may comprise a nano-colloid suspension of poly(phenyllactic-co-kojic-co-gluconic acid) (poly(PLKGA)), the nano colloid suspension of poly(PLKGA) comprising: a dispersed phase comprising a plurality of nanoparticles of poly(PLKGA); and a continuous phase comprising a medium of the nano-colloid suspension of poly(PLKGA).
Nº publicación: WO2026079308A1 16/04/2026
Applicant:
AGC INC [JP]
\uFF21\uFF27\uFF23\u682A\u5F0F\u4F1A\u793E
Absstract of: WO2026079308A1
The present invention provides: lipid nanoparticles that include a nucleic acid, cKK-E12, and DOPC, the molar ratio of the cKK-E12 to the DOPC content being 0.2–15.0; and a production method for the lipid nanoparticles that includes a step for preparing a lipid solution that includes cKK-E12, DOPC, a sterol, and a PEG lipid, a step for preparing a nucleic acid solution that includes a nucleic acid, and a step for mixing the lipid solution and the nucleic acid solution.
BOPI
Electronic site
